Wedbush Securities Inc. trimmed its stake in Omeros Co. (NASDAQ:OMER) by 21.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,670 shares of the biopharmaceutical company’s stock after selling 4,660 shares during the period. Wedbush Securities Inc.’s holdings in Omeros were worth $186,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of OMER. Brighton Jones LLC bought a new stake in Omeros in the third quarter worth $211,000. First Interstate Bank lifted its holdings in shares of Omeros by 100.0% in the 3rd quarter. First Interstate Bank now owns 10,000 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 5,000 shares during the last quarter. Freestone Capital Holdings LLC bought a new stake in shares of Omeros in the 3rd quarter worth about $285,000. Man Group plc bought a new stake in shares of Omeros in the 3rd quarter worth about $286,000. Finally, Advisors Asset Management Inc. bought a new stake in shares of Omeros in the 3rd quarter worth about $301,000. 47.19% of the stock is owned by institutional investors and hedge funds.
OMER traded down $0.08 on Monday, reaching $13.37. 23,517 shares of the company traded hands, compared to its average volume of 572,865. Omeros Co. has a one year low of $8.36 and a one year high of $27.00. The firm has a market capitalization of $653.79 million, a price-to-earnings ratio of -16.92 and a beta of 3.59.
Several equities research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. HC Wainwright set a $34.00 price objective on shares of Omeros and gave the stock a “buy” rating in a research note on Thursday, December 13th. Maxim Group reissued a “buy” rating and issued a $32.00 price objective on shares of Omeros in a research note on Friday, November 9th. Zacks Investment Research downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th. Finally, BidaskClub raised shares of Omeros from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 17th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $27.56.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Week Herald and is the property of of Week Herald. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://weekherald.com/2019/02/11/wedbush-securities-inc-has-186000-stake-in-omeros-co-omer.html.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Recommended Story: How are institutional investors different from individual investors?
Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER).
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.